因募资管理和使用问题，仙琚制药及相关责任人收警示函

Core Points - Zhejiang Xianju Pharmaceutical Co., Ltd. has received an administrative regulatory measure from the China Securities Regulatory Commission due to issues related to the management and use of raised funds [1][2] - The company has previously faced penalties for price monopoly related to the raw material dexamethasone phosphate sodium [5][6] Fund Management Issues - The Zhejiang Securities Regulatory Bureau found that Xianju Pharmaceutical had not followed proper procedures for the review and disclosure of certain raised funds, used raised funds for unrelated expenses, and mixed raised funds with its own funds when purchasing structured deposit financial products [2][3] Regulatory Actions - The regulatory measures include warning letters issued to the company and key personnel, including the chairman, general manager, financial director, and board secretary, which will be recorded in the securities and futures market integrity archives [3] Impact on Operations - Xianju Pharmaceutical stated that the administrative regulatory measures will not affect its normal production and business activities, and the company will comply with legal and regulatory requirements for timely information disclosure [4] Previous Penalties - Earlier in the year, Xianju Pharmaceutical was fined a total of 195 million yuan for engaging in price-fixing agreements that violated anti-monopoly laws, with the fine amounting to 4.88% of the company's audited revenue and 49.17% of its net profit attributable to shareholders for 2024 [5][6] Financial Performance - The company has experienced a decline in revenue and net profit in recent years, with revenues of 4.123 billion yuan and 4.001 billion yuan for 2023 and 2024, respectively, representing year-on-year declines of 5.85% and 2.98% [7] - In the first half of 2025, the company reported revenues of 1.869 billion yuan, a year-on-year decrease of 12.56%, with net profit attributable to shareholders at 308 million yuan, down 9.26% [7]